Cited by 12Bone fractures and treatmentsBone Tissue Engineering MaterialsMesenchymal stem cell research

Correction: Use of Autologous Human mesenchymal Stromal Cell/Fibrin Clot Constructs in Upper Limb Non-Unions: Long-Term Assessment

Open access
Giannotti, Stefano, Trombi, Luisa, Bottai, Vanna, Ghilardi, Marco, D'Alessandro, Delfo, Danti, Serena, Dell'Osso, Giacomo, Guido, Giulio +1 more·2013·PLoS ONE

Abstract

Background: Tissue engineering appears to be an attractive alternative to the traditional approach in the treatment of fracture non-unions.Mesenchymal stromal cells (MSCs) are considered an appealing cell source for clinical intervention.However, ex vivo cell expansion and differentiation towards the osteogenic lineage, together with the design of a suitable scaffold have yet to be optimized.Major concerns exist about the safety of MSC-based therapies, including possible abnormal overgrowth and potential cancer evolution. Aims:We examined the long-term efficacy and safety of ex vivo expanded bone marrow MSCs, embedded in autologous fibrin clots, for the healing of atrophic pseudarthrosis of the upper limb.Our research work relied on three main issues: use of an entirely autologous context (cells, serum for ex vivo cell culture, scaffold components), reduced ex vivo cell expansion, and short-term MSC osteoinduction before implantation.Methods and Findings: Bone marrow MSCs isolated from 8 patients were expanded ex vivo until passage 1 and short-term osteo-differentiated in autologous-based culture conditions.Tissue-engineered constructs designed to embed MSCs in autologous fibrin clots were locally implanted with bone grafts, calibrating their number on the extension of bone damage.Radiographic healing was evaluated with short-and long-term follow-ups (range averages: 6.7 and 76.0 months, respectively).All patients recovered limb function, with no evidence of tissue overgrowth or tumor formation.Conclusions: Our study indicates that highly autologous treatment can be effective and safe in the long-term healing of bone non-unions.This tissue engineering approach resulted in successful clinical and functional outcomes for all patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/annotation/e4403abb-b80e-43c5-be74-1bdb2c899d1c

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Osteogenically differentiated autologous BM-MSCs within fibrin clots can be safely used to heal non-unions.

    “The functional recovery seen through the use of osteogenically differentiated autologous BM-MSCs within fibrin clots shows they can be safely used to heal non-unions [39,93].”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [93]

    The correction (unpaginated) identifies the work as concerning mesenchymal stromal cell/fibrin-clot constructs in upper-limb non-unions and reports consistent short-term radiographic healing in the patients. It does not report functional recovery, establish that the cells were osteogenically differentiated, or assess safety, so those parts of the claim are unsupported by this copy. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In Giannotti et al., all eight patients with upper-limb non-union fractures treated with ex vivo expanded BM-MSCs embedded in autologous fibrin clots regained limb function at short and long term follow-ups (average 6.7 and 76 months) with no indications of excessive tissue growth or tumor development.

    “At both the short and long term follow-ups at an average time of 6.7 months and 76 months, respectively, all eight of the patients in this study regained the function of their limb with no indications of excessive tissue growth or tumor development.”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [93]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Giannotti, S., Trombi, L., Bottai, V., Ghilardi, M., D'Alessandro, D., Danti, S., Dell'Osso, G., Guido, G., & Petrini, M.
Affiliations
University of Pisa (IT)
Corresponding author
Trombi, Luisa
Venue
PLoS ONE
Published
2013-11-12
Volume
8
Issue
11
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4236603982
Cited by
12
References
51
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2016: 2
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Epidemiology › Bone fractures and treatments
  • Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
Keywords
nonunion, upper limb, mesenchymal stem cells, tissue engineering, bone marrow-derived MSCs, osteogenic differentiation, ex vivo cell expansion, bone grafting, long-term safety, bone regeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review